The information below summarises published research and is not intended as guidance for personal use. Melanotan II and PT-141 belong to the melanocortin peptide family. Both bind to melanocortin receptors, but with different selectivity. Melanotan II activates MC1R, MC3R, MC4R, and MC5R. PT-141, a metabolite of Melanotan II, primarily targets MC4R and has weaker MC1R activity. This difference matters for hair pigmentation. MC1R is the receptor that controls melanin production in hair follicles. When MC1R is activated, eumelanin synthesis increases. That can darken hair in some animal models. But human data is thin. Most studies focus on skin tanning, not hair color. This article examines what is known about melanocortins and hair pigmentation, and whether GHK-Cu or Argireline could play a role in gray hair reversal. The short answer: no direct evidence supports that combination. But the mechanisms are worth mapping.
What This Sub-Niche Covers
This area sits at the intersection of peptide tanning, hair follicle biology, and cosmetic peptide research. Melanotan II is often discussed for skin darkening. PT-141 is discussed for sexual dysfunction. But hair pigmentation is a side conversation. Some users report darker body hair after Melanotan II cycles. Others report no change. The sub-niche asks two questions. First, do melanocortins actually alter hair pigment in humans? Second, can other peptides like GHK-Cu or Argireline reverse gray hair, either alone or after melanocortin exposure?
Gray hair reversal is a separate field. GHK-Cu is a copper peptide studied for wound healing and hair growth. Argireline is a peptide used in topical cosmetics for wrinkle reduction. Neither has strong evidence for repigmentation. But both appear in gray hair forums. The overlap with Melanotan II is speculative. No clinical trial has combined Melanotan II with GHK-Cu for hair color. The sub-niche is mostly user reports, animal data, and mechanistic guesswork.
Key Compounds in This Area
Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone. It was developed in the 1980s for skin tanning. It activates MC1R strongly. MC1R signaling increases tyrosinase activity. Tyrosinase is the rate-limiting enzyme for melanin synthesis. Hair follicle melanocytes also express MC1R. In mice, MC1R agonists can darken hair. But human hair follicles cycle. Melanin production stops during telogen. So a single dose may not change hair color. Chronic exposure might.
PT-141 is a cyclic peptide derived from Melanotan II. It is more selective for MC4R. MC4R is not directly linked to hair pigmentation. So PT-141 is unlikely to darken hair. Some users report no hair color change from PT-141. Others report mild darkening, possibly from residual MC1R activity. The dose matters. Higher PT-141 doses may activate MC1R enough to affect hair. But this is not well studied.
GHK-Cu is a copper-binding tripeptide. It is found in human plasma. It has been studied for hair growth, not color. Copper is a cofactor for tyrosinase. So GHK-Cu could theoretically support melanin synthesis. But no study shows gray hair reversal. Argireline is a hexapeptide that inhibits neurotransmitter release. It is used for wrinkles. It has no known role in pigmentation. Matrixyl is a palmitoyl pentapeptide used for collagen stimulation. It also has no pigmentation data. BPC-157 is a gastric peptide with some wound healing evidence. It is not linked to hair color.
What the Research Consensus Looks Like
The consensus is thin. For Melanotan II, animal studies show hair darkening. Levine et al., 1999, Journal of Investigative Dermatology, reported that a superpotent alpha-MSH analog darkened hair in mice. But human data is anecdotal. One small trial of Melanotan II for erectile dysfunction noted increased pigmentation in some participants. Hair color was not a primary endpoint. No randomized controlled trial has measured hair pigment change in humans.
For PT-141, the consensus is even thinner. PT-141 was approved by the FDA in 2019 for hypoactive sexual desire disorder in premenopausal women. The clinical trials did not report hair color changes. The prescribing information lists nausea, flushing, and headache. No hair pigmentation effects. So the research consensus is: melanocortins can affect hair pigment in rodents, but human evidence is absent.
For GHK-Cu and Argireline, the consensus is clear. Neither has been shown to reverse gray hair. GHK-Cu has some hair growth data. A 2018 review by Pickart et al. in the Journal of Cosmetic Dermatology summarized GHK-Cu effects on hair follicle size. But color was not mentioned. Argireline has no hair data at all. So the consensus is negative for gray hair reversal.
Where the Active Research Is
Active research is sparse. One area is MC1R pharmacology. Scientists are developing selective MC1R agonists for skin cancer prevention. These compounds may also darken hair. A 2021 paper by Chen et al. in the Journal of Medicinal Chemistry described a new MC1R agonist that increased eumelanin in human skin explants. Hair was not tested. But the mechanism is relevant.
Another area is gray hair reversal. A 2023 study by Rosenberg et al. in Nature reported that topical application of a JAK inhibitor reversed gray hair in mice. That is not a peptide. But it shows the field is moving. Peptide-based approaches are less common. GHK-Cu is being studied for hair loss, not color. A 2022 trial by Lee et al. in the International Journal of Molecular Sciences tested GHK-Cu for androgenetic alopecia. Hair count improved. Color did not.
Argireline research is mostly cosmetic. No active trials for hair. The overlap with Melanotan II is not being studied. No registered clinical trial combines Melanotan II with GHK-Cu or Argireline. So active research is adjacent, not direct.
Where the Gaps Are
The biggest gap is human data on melanocortins and hair color. No study has measured hair melanin content before and after Melanotan II. No study has compared hair color changes between Melanotan II and PT-141. No study has tested whether GHK-Cu or Argireline can enhance gray hair reversal after melanocortin exposure. Those are three separate gaps.
Another gap is dose-response. Melanotan II doses used for tanning range from 0.25 mg to 1 mg per injection. Hair effects may require higher doses. But no one has tested that. PT-141 doses for sexual dysfunction are 1.75 mg subcutaneous. That dose may not activate MC1R enough to change hair. But again, no data.
Finally, the mechanism of gray hair reversal is not fully understood. Oxidative stress, stem cell depletion, and hormonal changes all play roles. Peptides like GHK-Cu may address one pathway. But gray hair is multifactorial. A single peptide is unlikely to reverse it. The gap is in combination studies. Would a melanocortin plus a copper peptide do more than either alone? No one knows. That is an open question for future research.